6 research outputs found
Gold compounds with anti-HIV and immunomodulatory activity
The human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) that subsequently develops remain major health concerns even after three decades since the first cases were reported. Successful therapeutic measures to address HIV/AIDS consist mostly of combinations of drugs targeting viral enzymes including reverse transcriptase (RT), protease (PR) and integrase (IN) as well as entry steps of the viral life cycle. The remarkable benefits (e.g. improved quality of life) derived from the use of these agents are unfortunately limited by toxicity to the host and the development of drug resistant viral strains. Drug resistance limits the repertoire of drug combinations available. Unfortunately, because latent forms of the virus exists, therapy has to be life-long and with new infections occurring every day, resistant strains tend to spread. To circumvent these problems, new drugs that inhibit resistant strains or work against new viral targets have to be developed. The history of gold compounds as potential inhibitors of HIV prompted this study in which twenty seven compounds consisting of gold(I), gold(III) and precursors from five classes were tested for drug-likeness, anti-HIV and immunomodulatory effects using wet lab and in silico methodologies. Cytotoxicity determination was done using viability dyes and flow cytometry. Cell proliferation profiles were monitored using the carboxyflourescein succinimidyl ester dye dilution technology and a real time cell analyser for confirming viability dye findings. The compounds’ effects on viral enzymes was determined using direct enzyme assays and in silico molecular modelling techniques. H and P nuclear magnetic resonance spectroscopy studies for determining stability revealed that the backbone chemical shifts of the compounds were relatively unchanged after one week (-20 and 37 ºC) when dissolved in dimethylsulfoxide. Eight of the gold compounds had drug-like properties comparable to clinically available drugs when in silico predictions were performed. The 50% cytotoxic dose of the compounds in human cells was between 1 and 20 μM (clinically relevant concentrations for gold compounds). Three gold(I) compounds inhibited viral infectivity at non-toxic concentrations and two gold(III) compounds did so at cytostatic (anti-proliferative mechanism that is also antiviral) concentrations. In the immunomodulatory assay, cytokine levels were altered by five compounds with one gold(I) and a gold(III) compound significantly reducing the frequency of CD4+ cells (an anti-viral function) from HIV+ donors (p= 0.005 and 0.027 respectively) when multi-parametric flow cytometry was performed. Inhibition of RT activity was predicted in in silico studies to be through interactions with the ribonuclease (RNase) H site although with poor stereochemical orientation while favourable binding predictions with the IN cofactor binding site were observed for some gold(III) complexes. Compounds predicted to interact with the RNase H site of RT and the IN cofactor site require structural modification to improve drug-likeness and binding affinity. The drug-like compound(s) which inhibited viral infectivity and lowered CD4+ cell frequency have potential for incorporation into virostatic cocktails (combination of cytostatic and directly anti-viral agent). Cytostatic agents are known to be less prone to drug resistance and because they lower CD4+ cell frequency, such compounds can potentially limit HIV immune activation.Thesis (PhD)--University of Pretoria, 2011.Biochemistryunrestricte
New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations : potential for incorporation into virostatic cocktails
Four bis(thiosemicarbazonate)gold(III) complexes (1–4) with a general formula [Au(L)]Cl {L=L1, glyoxal-bis
(N4-methylthiosemicarbazone); L2, glyoxal-bis(N4-ethylthiosemicarbazone); L3, diacetyl-bis(N4-
methylthiosemicarbazone); L4, diacetyl-bis(N4-ethylthiosemicarbazone)} were synthesised and screened
for activity against the human immunodeficiency virus (HIV). Complexes 1–4 were characterised using
1H-NMR and IR spectroscopy; and their purity established by micronanalysis. Complex 3 inhibited viral
infection of TZM-bl cells by 98% (IC50=6.8±0.6 μM) at a non toxic concentration of 12.5 μM while
complex 4 inhibited infection of these cells by 72 and 98% (IC50=5.3±0.4 μM) at concentrations of 6.25
and 12.5 μMrespectively. Themechanism of inhibition of infection in TZM-bl cells is presumably as a result
of the cytostatic or anti-proliferative activity that was observed for complex 4 in real time cell electronic
sensing (RT-CES) and carboxyflourescein succinimidyl ester (CFSE) analysis. Treatment of T lymphocytes
from HIV infected individuals with 4 decreased CD4+ T cell expression (p=0.0049) as demonstrated by
multi-parametric flow cytometry without suppressing cytokine production. None of the ligands (L1–L4)
demonstrated anti-viral activity, supporting the importance of metal (gold) complexation in these potential drugs.
Complexes 3 and 4were shown to have ideal lipophilicity values thatwere similarwhenshake flask (0.97±0.5 and
2.42±0.6) and in silico prediction (0.8 and 1.5) methods were compared. The activity and drug-like properties of
complexes 3 and 4 suggests that these novel metal-based compounds could be combined with virus inhibitory
drugs to work as cytostatic agents in the emerging class of anti-HIV drugs known as virostatics.The South African National Research Foundationhttp://www.elsevier.com/locate/jinorgbionf201
Impedance technology reveals correlations between cytotoxicity and lipophilicity of mono and bimetallic phosphine complexes
Label free impedance technology enables
the monitoring of cell response patterns post treatment
with drugs or other chemicals. Using this technology,
a correlation between the lipophilicity of metal
complexes and the degree of cytotoxicity was observed.
Au(L1)Cl (1), AuPd(L1)(SC4H8)Cl3 (1a) and
Au(L2)Cl (2) [L1 = diphenylphosphino-2-pyridine;
L2 = 2-(2-(diphenylphosphino)ethyl)-pyridine] were
synthesised, in silico drug-likeness and structure–
activity relationship monitored using impedance technology.
Dose dependent changes in cytotoxicity were observed for the metal complexes resulting in IC50s of
12.5 ± 2.5, 18.3 ± 8.3 and 16.9 ± 0.5 lM for 1, 1a
and 2 respectively in an endpoint assay. When a real
time impedance assay was used, dose-dependent
responses depicting patterns that suggested slower
uptake (at a toxic 20 lM) and faster recovery of the
cells (at the less toxic 10 lM) of the bimetallic
complex (1a) compared to the monometallic complexes
(1 and 2) was observed. These data agreed with
the ADMET findings of lower aqueous solubility of 1a
and non-ideal lipophilicity (AlogP98 of 6.55) over
more water soluble 1 and 2 with ideal lipophilicity
(4.91 and 5.03 respectively) values. The additional
coordination of a Pd atom to the nitrogen atom of a
pyridine ring, the sulfur atom of a tetrahydrothiophene
moiety and two chlorine atoms in 1a could be
contributing to the observed differences when compared
to the monometallic complexes. This report
presents impedance technology as a means of correlating
drug-likeness of lipophilic phosphine complexes
containing similar backbone structures and could
prove valuable in filtering drug-like compounds in a
drug discovery project.Technology Innovation Agency (TIA), the University of Pretoria.Organization for Women in Science for the Developing World (OWSD) formerly Third World Organization for Women in Science (TWOWS) and University of Johannesburg.http://link.springer.com/journal/105342016-08-31hb201
Chrysotherapy: evaluating gold compounds for anti-HIV activity
M.Sc.Background: The continuous emergence of drug resistant strains of HIV as a result of errors made by reverse transcriptase coupled with undesirable side effects of available drugs, latency problems, cost etc, warrants the continuous search for new drug candidates. Chrysotherapy which is the use of gold compounds for the treatment of various ailments has been practiced since 2500 BC. The use of gold compounds such as auranofin for the treatment of rheumatoid arthritis has lead to remission of this disease. Gold compounds such as auranofin not only prevented the progression of arthritis but also increased the CD4+ count of an HIV positive patient who was not on antiretrovirals. These compounds have been implicated in the treatment of cancers, autoimmune diseases and microorganism infections. Objectives: In this work, novel gold compounds were evaluated with the aim of identifying lead compound(s) that can eventually serve as anti-HIV agents. Materials and Methods: Eleven gold (I) phosphine complexes, four of their corresponding ligands (compound without gold atom), and a gold (III) complex were tested for the ability to inhibit reverse transcriptase (RT) and protease (PR) in direct enzyme assays. Uptake of the compounds by host cells was evaluated with inductively coupled plasma atomic emission spectrometry (ICP-AES). Potential toxicity of the gold compounds was screened for by viability dyes and flow cytometry assays. To determine inhibition of whole virus by other mechanisms in addition to RT or PR, p24 production by infected cells was evaluated. Prior to all these analysis, stability of compounds in solution was determined by 31P nuclear magnetic resonance (NMR) and UV-visible spectroscopy. Results: The compounds were shown to be stable in solution over a one week period and were taken up by both continuous cell lines and primary cells. Eight of the gold compounds significantly inhibited HIV-1 reverse transcriptase at concentrations of 25 and 250 μM while four compounds and the four ligands did not. In a fluorogenic assay against HIV-1 PR, four of the gold compounds demonstrated inhibitory activity. The gold compounds were toxic to cells lines but not to primary cells. One of the complexes (EK231) significantly reduced p24 (p=0.0042) production at a concentration of 25 μM. Conclusion: Data provided here suggests that the therapeutic benefits of these gold containing compounds as potential HIV-1 reverse transcriptase and protease inhibitors should be considered
Novel gold(I) phosphine compounds inhibit HIV-1 enzymes
The increasing incidence of human immunodeficiency virus (HIV) infection and the associated acquired immune deficiency syndrome (AIDS) mortality rates as well as the sometimes severe side effects of highly active anti retroviral therapy (HAART) warrants the continuous search for new, less toxic drug candidates. The anti-HIV activity (inhibition of reverse transcriptase-RT and protease-PR in direct enzyme assays) of eleven gold(I) phosphine compounds are reported here. Uptake of the compounds by peripheral blood mononuclear cells (PBMCs) was demonstrated by inductively coupled plasma atomic emission spectroscopy (ICP-AES) while the effect of the compounds on cell viability was assessed using flow cytometry with annexin V and propidium iodide (PI). Of the 11 gold compounds tested, 7 significantly (p o 0.05) inhibited RT activity at concentrations of 25 and 250 mM while 3 compounds significantly inhibited its activity at 6.25 mM. In the anti-protease assay, 4 of the compounds significantly inhibited the enzyme (p o 0.05) at 100 mM. All of the compounds were taken up by PBMCs (demonstrated by
ICP-AES) and were non toxic to these cells at clinically tolerable concentrations. The potential of these novel gold(I) phosphine compounds as anti-HIV agents is therefore promising and worthy of further investigation
HIV therapeutic possibilities of gold compounds
Highly active antiretroviral therapy
(HAART) has resulted in decreased mortality and
morbidity from the acquired immune deficiency
syndrome caused by the human immunodeficiency
virus (HIV). Drug resistance and toxicity of HAART
has led to the search for novel inhibitors of HIV
infection. Gold-based compounds have shown promising activity against a wide range of clinical conditions and microorganism infections including HIV-1. A typical example is auranofin which resulted in an elevated CD4? T-cell count in an HIV patient being treated for psoriatic arthritis. In addition, reports exist on gold-based inhibitors of reverse transcriptase (RT), protease (PR) and viral entry of host cells. These and other characteristics of goldbased
HIV drugs are reviewed here